Matrix metallopeptidase 9: a potential marker of residual risk?
Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS).
Caselli C, Di Giorgi N, Ragusa R, et al.
Vascul Pharmacol 2022;146:107098.
Non-alcoholic fatty liver disease, diabetic retinopathy and atherogenic dyslipidemia
Fatty liver and atherogenic dyslipidemia have opposite effects on diabetic micro- and macrovascular disease.
Hermans MP, Bouenizabila E, Amoussou-Guenou KD, et al.
Diabetes Metab Syndr 2022;16:102613.
Remnant cholesterol: a residual risk factor in Korean diabetes patients
Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study.
Huh JH, Han K, Cho YK, et al.
Cardiovasc Diabetol 2022;21(1):228.
MESA: Remnant-cholesterol and inflammation associate similarly with cardiovascular risk
Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA).
Chevli A, Islam T, Pokharel Y, et al.
). J Clin Lipidol 2022; doi: 10.1016/j.jacl.2022.09.005.
Remnant cholesterol predicts long-term mortality in patients with metabolic dysfunction-associated fatty liver disease
Menopausal status and ANGPTL8 and ANGPTL3 levels
Serum ANGPTL8 and ANGPTL3 as predictors of triglyceride elevation in adult women
Stefanska A, Bergmann K, Krintus M, et al.
CALIBER real-world registry: moderate hypertriglyceridaemia associates with MI risk
Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study.
Patel RS, Pasea L, Soran H, et al.
Cardiovascular Diabetology 2022;21:102.
High lipoprotein (a) levels increase risk for peripheral artery disease outcomes
High lipoprotein(a): a potential residual risk factor
Lipoprotein(a) and residual risk
Impact of lipoprotein(a) as a residual risk factor in long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statins.
Takahashi D, Wada H, Ogita M, et al.
Am J Cardiol 2022 Apr 1;168:11-16.
Targeting triglycerides to reduce residual risk: what are the implications for Europe?
Triglyceride-glucose trajectory associated with incident cardiovascular risk
Pemafibrate in European patients on statin
Apolipoprotein CIII predicts cardiovascular events in type 1 diabetes
Elevated triglycerides associated with diabetic kidney disease
High concentrations of triglycerides are associated with diabetic kidney disease in new-onset type 2 diabetes in China: Findings from the China Cardiometabolic Disease and Cancer Cohort (4C) Study.
Gong L, Wang C, Ning G, et al
Diabetes Obes Metab 2021;23:2551-60.
Explaining the REDUCE-IT versus STRENGTH controversy
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs.
Doi T, Langsted A, Nordestgaard BG
. Eur Heart J 2021;42:4807-17
Focus on lipoprotein(a): Lp(a)
Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: The Copenhagen General Population Study. Atherosclerosis 2021;
Kaltoft M, Sigvardsen PE, Afza S, et al.
Is apolipoprotein E associated with residual cardiovascular risk?
Serum apolipoprotein E levels predict residual cardiovascular risk in patients with chronic coronary syndrome undergoing first percutaneous coronary intervention and on-statin treatment.
Fukase T, Dohi T, Chikata Y, et al.
Atherogenic dyslipidemia associated with worse outcome in hospitalised COVID-19 patients
Remnant cholesterol linked with cardiovascular death in patients with type 2 diabetes and nephropathy
CAPTURE highlights gaps in cardiovascular disease management in type 2 diabetes patients across the globe
Remnant cholesterol and chronic kidney disease
Lipoprotein(a) and vulnerable plaque
Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: The Plaque at RISK (PARISK) study.
van Dam-Nolen DHK, van Dijk AC, Crombag GAJC, et al.
Diabetes escalates in the US: new data from NHANES
Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999-2018
Wang L, Li X, Wang Z, et al.
Residual cardiovascular risk: why a lifetime perspective matters
Mediterranean diet benefits cognitive function as well as cardiovascular risk
New review: global epidemiology of dyslipidaemias
LDL-TG and ANGPTL3 associate with cardiovascular events in older adults
Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A, Sun C, Selvin E, et al.
Eur J Prev Cardiol 2021;doi: 10.1093/eurjpc/zwaa152.
BIOSIGNAL highlights role of lipoprotein(a) in residual risk for stroke
Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study.
Arnold M, Schweizer J, Nakas CT, et al.
Eur Heart J 2021;42:2186-96.
ANGPTL4 variants and ischemic stroke
Single nucleotide polymorphisms in the and the SNP-SNP interactions on the risk of atherosclerotic Ischaemic stroke.
Shen C, Fan D, Fu H, et al.
BMC Neurol 2021;21(1):108.
ANGPTL3 haplotypes and susceptibility to cardiometabolic disease
A haplotype of the ANGPTL3 gene is associated with CVD risk, diabetes mellitus, hypertension, obesity, metabolic syndrome, and dyslipidemia.
Aghasizadeh M, Zare-Feyzabadi R, Kazemi T, et al.
Atherogenic dyslipidemia predicts COVID-19 severity
Higher remnant cholesterol promotes atherosclerosis progression
Genetic study reveals chromosome X variation linked with atherogenic lipids
Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices.
Natarajan P, Pampana A, Graham SE et al.
Nat Commun 2021;12:2182.
Inflammatory markers predict stroke outcome
Residual risk with concomitant diabetes and chronic kidney disease
Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease.
Hubbard D, Colantonio LD, Rosenson RS et al.
Cardiovasc Diabetol 2021;20:58
FGF21: another potential target to reduce residual risk?
Atherogenic index of plasma predicts progression of coronary atherosclerosis
Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors.
Won KB, Heo R, Park HB et al.
Atherosclerosis 2021; DOI:
New from Look-AHEAD: atherogenic dyslipidemia and cardiovascular outcome
Does higher HDL cholesterol concentration protect against severe COVID-19 infection?
Mendelian randomization, lipid traits and coronary artery disease
A Call to Action on Air Pollution
Taking a stand against air pollution—the impact on cardiovascular disease. A Joint Opinion From the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology.
Brauer M, Casadei M, Harrington RA et al.
Circulation 2021; DOI: 10.1161/CIRCULATIONAHA.120.052666
What’s new about SPPARMα?
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the metabolic syndrome: is pemafibrate light at the end of the tunnel?
Fruchart JC, Hermans MP, Fruchart-Najib J, Kodama T.
Curr Atheroscler Rep 2021;23(1):3.
Increased remnant cholesterol: a marker of early atherosclerotic disease?
Triglycerides: a risk factor for both dementia and atherosclerotic cardiovascular disease
Triglycerides as a shared risk factor between dementia and atherosclerotic cardiovascular disease: a study of 125,727 individuals.
Nordestgaard LT, Christoffersen M, Afzal S, et al.
Clin Chem 2021;67:245-55.
ACS patient pathway and lipid goal achievement
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.
Landmesser U, Pirillo A, Farnier M et al.
Atheroscler Suppl 2020;42:e49-e58.
Kinetic insights into the effects of PCSK9 inhibition on TG-rich lipoproteins
Admission interleukin-1β linked with mortality and recurrent events in MI patients
Pemafibrate: potential role in non-alcoholic fatty liver disease?
Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.
Shinozaki S, Tahara T, Kawarai Lefor A, Ogura M.
Clin Exp HEPATOL 2020; 6, 3: 270–274
Pemafibrate blocked inflammation in an atherosclerosis model
Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knockout swine with balloon injury.
Konishi H, MiyauchiI K, Onishi A, et al.
PLoS ONE 2020:15(11): e0241195.
Residual cardiovascular risk: what do we know now?
Residual cardiovascular risk at low LDL: Remnants, lipoprotein(a), and inflammation.
Hoogeveen RC, Ballantyne CM.
Clin Chem 2021;67: 143-153.
Apolipoprotein CIII deficiency protects against atherosclerosis
Remnant cholesterol: looking beyond cardiovascular risk
Is VLDL cholesterol the ‘new kid’ for cardiovascular risk prediction?
VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins.
Balling M, Afzal S, Varbo A, et al.
J Am Coll Cardiol 2020;76:2725-35.
Quantifying diabetes-associated residual risk
Pemafibrate shows benefit in severe hypertriglyceridaemia
Marked effects of novel selective peroxisome proliferator-activated receptor alpha modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Iitake C, Masuda D, Koseki M, Yamashita S
Cardiovasc Diabetol 2020;19:201.
Residual inflammatory risk despite intensive lipid lowering
More from CANTOS: Canakinumab reduced the total cardiovascular disease burden
Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS Trial.
Everett BM, MacFadyen JG, Thuren T, et al.
J Am Coll Cardiol 2020;76:1660-70.
JUPITER: HDL functionality may explain the ‘HDL paradox’
Anti-inflammatory HDL function, incident cardiovascular events, and mortality: a secondary analysis of the JUPITER randomized clinical trial.
Ajala ON, Demler OV, Liu Y, et al
J Am Heart Assoc 2020;9:e016507.
Back to the future for HDL: a role beyond cardiovascular disease?
Apolipoprotein CIII levels predict recurrent cardiovascular events
Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.
Katzmann JL, Werner CM, Stojakovic T, et al.
Lipids in Health and Disease 2020;19:116.
CNIC polypill improves atherogenic dyslipidaemia in a real-world primary prevention setting
The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico.
Gómez-Álvarez E, Verdejo J, Ocampo S, et al.
Int J Cardiol Heart Vasc 2020;29:100545.
Pemafibrate in non-alcoholic fatty liver disease?
Apolipoprotein CIII and stroke risk
Increased incidence of ischemic cerebrovascular events in cardiovascular patients with elevated apolipoprotein CIII.
Olivieri O, Cappellari M, Turcato G et al
BARI 2D trial: Elevated triglycerides and residual cardiovascular risk
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial).
Nelson AJ, Navar AM, Mulder H, et al.
Am J Cardiol 2020;132:36-43.
Diet, remnant cholesterol and Non-Alcoholic Fatty Liver Disease (NAFLD)
The effect of three Mediterranean diets on remnant cholesterol and Non-Alcoholic Fatty Liver Disease: a secondary analysis.
Campanella A, Iacovazzi PA, Misciagna G, et al.
Residual cardiovascular risk: an evolving concept
Inflammatory residual risk in diabetes: how prevalent?
Insights from CIRT into management of residual cardiovascular risk
Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial
Ridker PM, MacFadyen JG, Glynn RJ et al.
Eur Heart J 2020; doi: 10.1093/eurheartj/ehaa160.
Understanding remnants and their role in cardiovascular disease in diabetes
Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease.
Chait A, Ginsberg HN, Vaisar T et al.
Triglyceride: high-density lipoprotein cholesterol ratio and risk of type 2 diabetes
Chronic kidney disease and nonalcoholic fatty liver disease linked in type 2 diabetes
Common and unique factors and the bidirectional relationship between chronic kidney disease and nonalcoholic fatty liver in type 2 diabetes patients.
Lee YJ, Wang CP, Hung WC, et al.
Diabetes Metab Syndr Obes 2020;13:1203-14.
ACCORDION: legacy survival benefit from fibrate treatment in dyslipidaemia patients
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
Zhu L, Hayen A, Bell KJL.
Cardiovasc Diabetol 19, 28 (2020).
US NHANES data highlight high prevalence of elevated triglycerides despite statin therapy
ACC.20/WCC virtual meeting: Benefit in REDUCE-IT linked to eicosapentaenoic acid levels
News with pemafibrate, a novel SPPARMα agent
Pemafibrate, a new selective PPARα Modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases.
Yamashita S, Masuda D, Matsuzawa
Y. Curr Atheroscler Rep 2020;22(1):5.
Alirocumab in atherogenic dyslipidemia
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
Colhoun HM, Leiter LA, Müller-Wieland D, et al.
Cardiovasc Diabetol 2020;19:14.
Novel approaches in hypertriglyceridemia: dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist
New review: Triglycerides and residual risk
New US National Lipid Association Statement focuses on icosapent ethyl for management of triglyceride-related residual risk.
National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE, Jacobson TA, Maki KC et al.
J Clin Lipidol 2019;13:860-872.
HOT OFF THE PRESS: STRENGTH Cardiovascular outcomes study terminated
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH): ClinicalTrials.gov Identifier: NCT02104817
ClinicalTrials.gov Identifier: NCT02104817
Omega-3 supplementation and cardiovascular disease
Quantifying atherogenic lipoproteins: Practical guidance
Insights into PPAR-alpha polymorphisms
Low HDL-C: a role in monitoring plasma triglyceride levels?
Real-world residual cardiovascular risk associated with elevated triglycerides
Pemafibrate: promising effects in a mouse model of retinopathy
Remnant cholesterol associated with coronary atheroma progression
ANGPTL3 variants and risk of ischaemic stroke
Metabolic syndrome recovery reduces risk for cardiovascular events
Altered risk for cardiovascular events with changes in the metabolic syndrome status: a nationwide population-based study of approximately 10 million persons.
Park S, Lee S, Kim Y et al.
Ann Intern Med 2019; doi:10.7326/M19-0563.
Residual vascular risk in diabetes – will the SPPARM alpha concept hold the key?
Residual cardiovascular risk: Dyslipidaemia criteria need to be tighter
New meta-analysis: triglycerides and cardiovascular risk in type 2 diabetes
Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies.
Ye X, Kong W, Zafar MI, Chen LL.
Cardiovasc Diabetol 2019;18(1):48
PCSK7: Linking atherogenic dyslipidaemia and inflammation in non-alcoholic fatty liver disease?
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients.
Dongiovanni P, Meroni M, Baselli G et al.
J Lipid Res 2019;60:1144-53.
Remnant cholesterol and coronary atherosclerotic plaque burden
Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography.
Lin A, Nerlekar N, Rajagopalan A et al.
Remnant lipoproteins contain one-third of total plasma cholesterol
A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals.
Balling M, Langsted A, Afzal S
Non-alcoholic fatty liver disease predicts coronary artery disease
Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects
Gummesson A, Stromberg U, Schmidt C et al.
PloS one 2018; 13:e0202666.
Novel variant for high triglycerides in Arab population
Triglycerides predict first cardiovascular events in diabetes
Elevated triglycerides contribute to residual cardiovascular risk
A link between elevated triglycerides and risk for peripheral artery revascularization?
Toth PP, et al
Presented at: European Society of Cardiology Congress; Aug. 25-29, 2018; Munich
News flash: REDUCE-IT meets primary endpoint
AIM-HIGH: post hoc analysis suggests benefit in atherogenic dyslipidaemia
Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial.
Toth PP, Jones SR, Slee A et al.
J Clin Lipidol 2018;2:741-7.
Dyslipidemia International Survey-China survey highlights atherogenic dyslipidaemia
Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy.
Zhao W, Zheng XL, Jiang ZN et al.
Int J Cardiol 2017;248:355-60.
Do genome-editing technologies have a role in managing atherogenic dyslipidaemia?
Obesity a driver of inadequate control of triglycerides in younger diabetes subjects in Japan
Atherogenic dyslipidaemia prevalent in China
Targeting triglycerides: therapeutic potential of ANGPTL3 and apoC-III?
More news from ANCHOR: Focus on women with high triglycerides
TNT analysis: Higher triglyceride-rich lipoprotein-cholesterol associated with increased cardiovascular risk
Well-being linked with lower triglycerides and high HDL-C
Persistently high psychological well-being predicts better HDL cholesterol and triglyceride levels: findings from the midlife in the U.S. (MIDUS) longitudinal study.
Radler BT, Rigotti A, Ryff CD.
Lipids in Health and Disease (2018) 17:1
Serum C-peptide: a contributor to lipid-related residual risk in the elderly?
Cost of diabetic complications in Germany
Atherogenic dyslipidaemia common in Chinese patients at LDL-C goal
Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy.
Zhao W, Zheng XL, Jiang ZN et al.
Int J Cardiol 2017;248:355-60.
Metabolic syndrome severity predicts future coronary events in type 2 diabetes
Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes.
Gurka MJ, Guo y, Filipp SL, DeBoer MD.
Cardiovasc Diabetol (2018) 17:17.
Adverse effects of high HDL-C?
Empagliflozin decreases remnant cholesterol in diabetes patients
Plaque profile in diabetes
Plaque volume and plaque risk profile in diabetic vs. non?diabetic patients undergoing lipid?lowering therapy: a study based on 3D intravascular ultrasound and virtual histology.
Kovarnik T, Chen Z, Mintz GS et al.
Cardiovasc Diabetol 2017;16:156.
Triglycerides and Alzheimer’s disease?
Impaired HDL anti-inflammatory activity in diabetes
The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovasc Diabetol 2017;16:132.
Ebtehaj S, Gruppen EG, Parvizi M et al.
Cardiovasc Diabetol 2017;16:132.
Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: What matters in the real world?
Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? Data from a multicenter registry cohort study in Taiwan.
Yeh Y-T, Yin W-H, Tseng W-K et al.
PLOS One 2017; doi.org/10.1371/journal.pone.0186861
Missense APOC3 variant lowers plasma triglycerides
A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA, Zeng X, Millar JS et al.
Nat Med 2017;23:1086-94.
New review of pemafibrate, novel SPPARMalpha
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.
Cardiovasc Diabetol 2017;16:124.
Obesity a key driver of the diabetes burden in China.
Obesity, genetic risk and triglycerides
Adiposity and genetic factors in relation to triglycerides and triglyceride-rich lipoproteins in the Women's Genome Health Study.
Ahmad S, Mora S, Franks PW et al.
Clin Chem 2017; doi: 10.1373/
Pemafibrate (K-877) attenuates postprandial hypertriglyceridemia in mice
A novel Selective PPAR? Modulator (SPPARM?), K-877 (Pemafibrate), attenuates postprandial hypertriglyceridemia in mice.
Sairyo M, Kobayashi T, Masuda D, Kanno K, Zhu Y, Okada T, Koseki M, Ohama T, Nishida M, Sakata Y, Yamashita S.
J Atheroscler Thromb 2017. doi: 10.5551/jat.39693. [Epub ahead of print]
Atherogenic dyslipidaemia in rheumatoid arthritis
High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein.
Rodríguez-Carrio J, Alperi-López M, López P, López-Mejías R, Alonso-Castro S, Abal Fet al.
J Clin Lipidol 2017;11:1043-54.
Nonfasting triglycerides/high-density lipoprotein cholesterol ratio predicts cardiovascular events after PCI
Target non-HDL-C to reduce residual cardiovascular risk factors in diabetes
Composite endpoints in clinical trials in type 2 diabetes
Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point?
Marx N, McGuire DK, Perkovic V et al.
Diabetes Care 2017; 40: 1144-51.
Is the ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid a Residual Risk Marker?
Alzheimer’s dementia linked with metabolic syndrome
TECOS: underachievement on targets in secondary prevention diabetes patients
EURIKA: Need to do better in managing atherogenic dyslipidaemia in primary prevention
Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP, Banegas JR, Roy C et al.
BMC Cardiovascular Disorders 2017;17:160.
**NEWS ALERT** CANTOS and REVEAL studies both meet the primary study endpoint
**NEWS ALERT** CANTOS and REVEAL studies both meet the primary study endpoint
Is FGF21 a potential target in hypertriglyceridaemia?
Remnant lipoproteins and cardiovascular risk
Are triglycerides causal in cardiovascular disease?
Atherogenic dyslipidaemia is predictive of incident CHD in China
Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography.
Ling Y, Jiang J, Wu B, Gao X.
J Clin Lipidol 2017;11:646-56.
Does road traffic noise/air pollution play a role in cardiometabolic disease risk?
Gender disparity in lipid targets for men and women in the Arabian Gulf
Gender disparity in lipid target achievements in high and very high atherosclerotic cardiovascular disease risk patients in the Arabian Gulf.
Al-Zakwani I, Shehab A, Al-Hinai AT et al.
Curr Vasc Pharmacol. 2017;15:51-8.
HDL-cholesterol and triglycerides linked with insulin secretion in non-diabetic individuals
Plasma HDL-cholesterol and triglycerides, but not LDL-cholesterol, are associated with insulin secretion in non-diabetic subjects
Natali A, Baldi S, Bonnet F et al.
Do peroxisome proliferator-activated receptor targeted treatments have a role in fatty liver disease?
The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
Sun X, Zhang Y, Xie M
Acta Pharm 2017;67:1-13.
Pemafibrate (K-877) add-on to statin: More trials report
Is inflammation a key determinant of the atherogenicity of remnant cholesterol?
Increased burden of coronary artery disease with elevated BMI
Obesity, metabolic syndrome and cardiovascular prognosis: from the Partners coronary computed tomography angiography registry.
Hulten EA, Bittencourt MS, Preston R et al.
Cardiovascular Diabetology 2017;16:14.
Call for action for dyslipidaemia in Middle East
Abdominal adiposity and risk for type 2 diabetes and coronary heart disease
Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease.
Emdin CA, Khera AV, Natarajan P et al.
What can we look forward to at the 66th Annual Scientific Sessions of the American College of Cardiology, Washington DC, 17-19 March, 2017?
Impairment of HDL function in post-infarct patients
HDL function is impaired in acute myocardial infarction independent of plasma HDL cholesterol levels.
Annema W, Willemsen HM, de Boer JF et al.
J Clin Lipidol 2016;10:1318-28
Dyslipidaemia may precede peripheral insulin resistance
Changes in triglycerides and high-density lipoprotein cholesterol may precede peripheral insulin resistance, with 2-h insulin partially mediating this unidirectional relationship: a prospective cohort study.
Han T, Cheng Y, Tian S et al.
Cardiovasc Diabetol 2016;15(1):154
Economic benefits of targeting both cholesterol and triglycerides
Triglycerides:HDL ratio predicts worse outcomes after acute ischaemic stroke
Residual cardiovascular risk in a real-world setting
News from American Heart Association Scientific Sessions 2016, 11-15 November, New Orleans, USA
A link between APOC3, triglycerides and coronary disease via miR-4271 binding?
An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site.
Hu SL, Cui GL1 Huang J, Jiang JG, Wang DW.
Sci Rep 2016;6:32700. doi: 10.1038/srep32700.
Peripheral artery disease associated with increased cardiovascular risk
Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.
Mohammedi K, Woodward M, Hirakawa Y et al.
Cardiovasc Diabetol 2016;15:129.
New analysis highlights need for aggressive lipid mana
Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN.
Stegman B, Shao M, Nicholls SJ et al.
Atherosclerosis 2016; Epub ahead of print.
Dyslipidaemia management in type 2 diabetes still far from optimal
Hot off the Press: Topline results for GLAGOV with the PCSK9 inhibitor evolocumab look good
Is the polypill a cost-effective option to reduce residual cardiovascular risk?
SPIRE outcomes studies with bococizumab
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
Ridker PM, Amarenco P, Brunell R et al
Am Heart J 2016;178:135-144.
Controversy about lipid fractions and risk for CAD and diabetes
News from ESC Congress 2016 Rome
Triglyceride/HDL ratio predicts multivessel coronary artery disease in ACS
Impact of triglycerides/HDLcholesterol ratio on coronary artery disease severity and in shortterm outcome of patients with acute coronary syndromes
Timoteo AT, Rosa SA, Nogueira MA et al
Eur Heart J 2016;37(Abstract Supplement): 1390.
News from ESC Congress 2016 Rome
Mendelian randomization study shows the benefit of targeting multiple risk factors
A naturally randomized trial comparing the effect of long-term exposure to lower LDL-C, lower SBP, or both on the risk of cardiovascular disease.
Ference B et al.
ESC Congress 2016 - Abstract 3163
News from ESC Congress 2016 Rome
Updated ESC/EAS dyslipidaemia guidelines launched
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).
Catapano AL, Graham I, De Backer G et al.
Eur Heart J 2016 Aug 27. pii: ehw272. [Epub ahead of print].
Association of microvascular and macrovascular diabetic complications
Impact of diabetic retinopathy on vulnerability of atherosclerotic coronary plaque and incidence of acute coronary syndrome.
Kurihara O, Takano M, Mizuno K et al.
Am J Cardiol 2016; Epub ahead of print.
Anagliptin may mediate benefit via reduction in remnant cholesterol
Anagliptin, a dipeptidyl peptidase-4 inhibitor ameliorates arterial stiffness in association with reduction of remnant-like particle cholesterol and alanine transaminase levels in type 2 diabetic patients.
Tahara N1, Yamagishi SI, Bekki M et al.
Curr Vasc Pharmacol 2016 Jun 24. [Epub ahead of print]
NIPPON DATA 90: Non-HDL cholesterol is a predictor of long-term coronary mortality
Relationship between non-high-density lipoprotein cholesterol and the long-term mortality of cardiovascular diseases: NIPPON DATA 90
Ito T, Arima H2, Fujiyoshi A1 et al.
Int J Cardiol 2016;220:262-7.
Targeting atherogenic dyslipidaemia: the next lipid frontier
Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol.
Xiao C, Dash S, Morgantini C et al
Volanesorsen: favourable effects on atherogenic dyslipidaemia in type 2 diabetes
Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes
Digenio A, Dunbar RL, Alexander VJ et al.
Diabetes Care 2016;39:1408-15.
AIM-HIGH: should we refocus on HDL subfractions?
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Albers JJ, Slee A, Fleg JL et al.
Atherosclerosis 2016 Epub ahead of print.
Fitness and atherogenic dyslipidaemia
Positive data with apolipoproteinCIII antisense agent
HDL cholesterol paradox in residual cardiovascular risk
HDL cholesterol as a residual risk factor for vascular events and all-cause mortality in patients with type 2 diabetes.
Sharif S, van der Graaf Y, Nathoe HM et al.
Diabetes Care 2016 Epub ahead of print.
ACCORDION: Benefit of fenofibrate on diabetic retinopathy did not persist long-term
Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
Diabetes Care 2016; Epub ahead of print: http://dx.doi.org/10.2337/dc16-0024
Homocysteine levels are not associated with an atherogenic lipid profile
Serum homocysteine is not independently associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-21) study.
Lupton JR, Quispe R, Kulkarni K et al.
Lipid-lowering for primary cardiovascular prevention in type 1 diabetes
Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes
Hero C, Rawshani A, Svensson AM et al.
Diabetes Care 2016 Jun; 39(6): 996-1003
Triglycerides predictive of arterial stiffness
Triglycerides are a predictive factor for arterial stiffness: a community-based 4.8-year prospective study
Wang X, Ye P, Cao R, Yang X, Xiao W, Zhang Y, Bai Y, Wu H
Lipids Health Dis 2016;15(1):97.
HDL mimetic peptide CER-522 improves left ventricular diastolic dysfunction
HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits.
Merlet N, Busseuil D, Mihalache-Avram T et al.
Int J Cardiol 2016;215:364-71.
ASGR1; the next PCSK9 story?
Fibroblast growth factor 21: potential for diagnosis of early stage diabetic retinopathy?
Study identifies novel variant for triglycerides
Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution
Patel AP, Peloso GM, Pirruccello JP, Johansen CT, Dubé JB, Larach DB, Ban MR, Dallinge-Thie GM, Gupta N, Boehnke M, Abecasis GR, Kastelein JJP, Hovingh GK, Hegele RA, Rader DJ, Kathiresan S.
Atherosclerosis Epub ahead of print, 23 April 2016.
HDL characteristics beyond HDL cholesterol concentration: marker or mediator of coronary atherosclerosis?
Patients with coronary endothelial dysfunction have impaired cholesterol efflux capacity and reduced HDL particle concentration.
Monette JS, Hutchins PM, Ronsein GE, Wimberger J, Irwin AD, Tang C, Sara JD, Shao B, Vaisar T, Lerman A, Heinecke JW
Circ Res 2016; Published online before print April 25, 2016,
Triglyceride/HDL-C ratio: indicator of risk of sleep apnoea syndrome
Serum triglyceride levels in relation to high-density lipoprotein cholesterol (TG-HDL) ratios as an efficient tool to estimate the risk of sleep apnea syndrome in non-overweight Japanese men
Shimizu Y, Yoshimine H, Nagayoshi M, Kadota K, Takahashi K, Izumino K, Inoue K, Maeda T.
Environ Health Prev Med. 2016 Apr 19. [Epub ahead of print].
Death knell for CETP inhibition? More details on ACCELERATE with evacetrapib
Death knell for CETP inhibition? More details on ACCELERATE with evacetrapib
Dr. Stephen J. Nicholls
The American College of Cardiology Annual Scientific Session, Chicago, IL, April 3, 2016.
HDL cholesterol implicated in hypertension
Isolated low HDL cholesterol prevalent in Peru
Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study
Lazo-Porras M, Bernabe-Ortiz A, Málaga G et al
Low HDL cholesterol and risk for chronic kidney disease
Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression.
Bowe B, Xie Y, Xian H et al.
Kidney Int 2016;89:886-96
VADT: Higher HDL cholesterol decreases risk of progression of diabetic retinopathy
Not all HDL cholesterol is good
Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.
Zanoni P, Khetarpal SA, Larach DB et al; CHD Exome+ Consortium; CARDIoGRAM Exome Consortium; Global Lipids Genetics Consortium.
Triglyceride-rich lipoproteins and cardiovascular disease: bringing the story together
Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology.
Circ Res 2016;118:547-63.
SPIKE: a role for dipeptidyl peptidase 4 inhibitors in atheroma regression
Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). A randomized controlled trial.
Mita T, Katakami N, Shiraiwa T et al; on behalf of the Collaborators on the Sitagliptin Prevention Study of Intima-Media Thickness Evaluation (SPIKE) Trial
Diabetes Care 2016. pii: dc152145. [Epub ahead of print]
Apolipoprotein B predicts subclinical atherosclerosis
Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification. The CARDIA Study.
Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM.
J Am Coll Cardiol 2016;67:193–201.
Mechanistic insights into how FGF21 lowers triglycerides
Legacy effects of statins: WOSCOPS
Long term safety and efficacy of lowering LDL cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study
Ford I, Murray H, McCowan C, Packard CJ
Circulation 2016 [Epub ahead of print].
Diet superior to exercise for improving dyslipidaemia in high risk patients
Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial.
Pedersen LR, Olsen RH, Anholm C et al.
Atherosclerosis. 2016 Jan 13;246:221-228
Empowering the diabetic patient improves cardiovascular and microvascular outcomes
Macrovascular and microvascular disease in obese patients with type 2 diabetes attending structured diabetes education program: a population-based propensity-matched cohort analysis of Patient Empowerment Programme (PEP)
Wong CK, Wong WC, Wan EY et al.
Endocrine. 2016 Jan 19. [Epub ahead of print]
Polypill benefits modified by cardiovascular risk
Statin intolerance: a contributor to residual cardiovascular risk?
Novel genetic variants associated with lipids identified in Asian cohorts
Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese.
Tang CS, Zhang H, Cheung CY et al
Nature communications 2015; 6:10206.
Medias role in statin adherence and impact on cardiovascular risk reduction
New review focuses on management of residual risk after statin therapy
Proteomic analysis highlights differences in apolipoprotein CIII association with triglycerides
The association of human apolipoprotein C-III sialylation proteoforms with plasma triglycerides.
Yassine HN, Trenchevska O, Ramrakhiani A et al.
PLoS One 2015;10:e0144138
Remnant cholesterol linked with premature MI
Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol.
Goliasch G, Wiesbauer F, Blessberger H et al.
J Clin Lipidol 2015;9(6):801-806.
Genetic variants of peroxisome proliferator-activated receptor ? linked with susceptibility to diabetic retinopathy
SPEAD-A: Alogliptin slows progression of atherosclerosis in type 2 diabetes
Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)
Mita T, Katakami N, Yoshii H et al.
Diabetes Care 2015. pii: dc150781. [Epub ahead of print]
ASPIRE-S study: action needed to improve prevention after ischaemic stroke
TG/HDL cut-off for cardiovascular risk differs with ethnicity
Comparison between European and Iranian cutoff points of triglyceride/high-density lipoprotein cholesterol concentrations in predicting cardiovascular disease outcomes.
Gharipour M, Sadeghi M, Dianatkhah M et al.
J Clin Lipidol 2015 in press.
Study suggests genetic connection between dyslipidaemia and type 2 diabetes
Genetic linkage of hyperglycemia and dyslipidemia in an intercross between BALB/cJ and SM/J Apoe-deficient mouse strains.
Wang Q, Grainger AT, Manichaikul A et al.
BMC Genetics 2015;16:133.
Evacetrapib: insights into effects on HDL
Cholesterol efflux capacity and pre-Beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib.
Nicholls SJ, Ruotolo G, Brewer HB et al.
J Am Coll Cardiol 2015;66:2201–10.
Frequent short bursts of activity improve postprandial triglycerides
Cochrane review supports calls for a definitive fibrate outcomes study
Trial news: Outcomes study with RVX-208 (apabetalone)
AHA 2015 : EURIKA: Atherogenic dyslipidaemia prevalent despite high-intensity statin therapy
AHA 2015 : Focus on triglycerides
Increased triglyceride levels are associated with endothelial dysfunction: FMD-Japan Registry.
Kajikawa M, Higashi Y, Maruhashi T et al.
Circulation 2015; 132: 10041.
AHA 2015 : ACCORDION: follow-up of ACCORD brings new data
The Effect of Combined Statin/Fibrate Therapy on Cardiovascular Disease is Influenced by Sex and Dyslipidemia: ACCORDION-Lipid Long-Term Follow-up.
Elam MB, Lovato LC, Ginsberg HN et al on behalf of the ACCORD/ACCORDION Study Group.
Innovative approaches to improving lifestyle adherence in secondary prevention
Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial.
Chow CK, Redfern J, Hillis GS et al.
JAMA 2015; 314:1255-1263.
High-dose statin therapy ameliorates the impact of elevated triglycerides
Triglycerides associate with carotid artery intima-media thickness
Triglyceride/HDL ratio a predictor of non-alcoholic fatty liver disease?
PCSK9 modulates the function of CD36 and triglyceride metabolism
HDL cholesterol associated with inflammation in ACS
Levels of High-density Lipoprotein Cholesterol are Associated with Biomarkers of Inflammation in Patients with Acute Coronary Syndrome
González-Pacheco H, Amezcua-Guerra LM, Vazquez-Rangel A et al.
Atherosclerosis 2015; Epub ahead of print
Accumulation of small chylomicron particles in moderate hypertriglyceridaemia
Targeting lipoprotein(a) to reduce aortic valve stenosis
PCSK9 inhibition: potential impact on triglycerides?
PREDIMED: Mediterranean diet protects against diabetic microvascular complications
Mediterranean diet, retinopathy, nephropathy, and microvascular diabetes complications: A post hoc analysis of a randomized trial.
Diaz-Lopez A, Babio N, Martinez-Gonzalez MA et al.
Diabetes Care 2015; Epub ahead of print.
Atherogenic dyslipidaemia more prevalent in type 2 diabetes ‘Night owls’
Evening chronotype in T2DM linked to atherogenic dyslipidemia and lower prevalence of cerebrovascular disease.
Hermans MP, Camara S, Ahn SA, Rousseau MF
**News from American Diabetes Association's Scientific Sessions, June 5 - 9, 2015, Boston, Massachusetts**
Treatment of patients with elevated triglycerides and low HDL-C in Europe: Results from EURIKA.
Halcox JP, Pasquet B, Hendriksson KM
Dyslipidaemia and diabetic macular oedema: is there more than meets the eye?
Low HDL-C plus elevated CRP levels predict worse outcome following PCI
Impact of combined C-Reactive Protein and High-Density Lipoprotein Cholesterol levels on long-term outcomes in patients with coronary artery disease after a first percutaneous coronary intervention.
Ogita M, Miyauchi K, Tsuboi S et al
Atherosclerosis 2015; Epub ahead of print
New meta-analysis shows PCSK9 monoclonal therapies are safe and effective
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.
Zhang XL, Zhu QQ, Zhu L et al
BMC medicine 2015; 13:123
Resistin: a novel marker of residual vascular risk in statin-treated patients
On-statin resistin, leptin, and risk of recurrent coronary events after hospitalization for an acute coronary syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)
Khera AV, Qamar A, Murphy SA et al.
Am J Cardiol 2015; Epub ahead of print.
Peroxisome proliferator-activated receptor-alpha increases cholesterol efflux capacity in metabolic syndrome
Potent peroxisome proliferator-activated receptor-alpha agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.
Khera AV, Millar JS, Ruotolo G et al.
European Heart J 2015 [Epub ahead of print].
Does increased uptake of atherogenic lipoproteins from interstitial fluid in type 2 diabetes explain accelerated atherosclerosis?
No increased risk of diabetes with PCSK9 loss-of-function variant
Cardiac autonomic neuropathy evident in early type 2 diabetes
The prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS).
Zoppini G, Cacciatori V, Raimondo D et al.
Diabetes Care 2015; Epub ahead of print.
News from ANCHOR: icosapent ethyl reduced atherogenic lipoprotein particle concentration in statin-treated patients with elevated triglycerides
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
Ballantyne CM, Braeckman RA, Bays HEet al.
J Clin Lipidol 2015; Epub ahead of print]
Elevated triglycerides and cardiovascular risk in Korea
Insights into the renoprotective effects of fenofibrate
Renoprotective effects of fenofibrate via modulation of LKB1/AMPK mRNA expression and endothelial dysfunction in a rat model of diabetic nephropathy.
Al-Rasheed NM, Al-Rasheed NM, Attia HAet al.
Pharmacology 2015 [Epub ahead of print]
Adiponectin implicated in diabetic retinopathy
Time to re-evaluate the role of HDL in cardiovascular risk?
Aging and population growth key drivers for CVD rates
TG/HDL-C ratio: an important prognostic indicator of risk
The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
Sonmez A, Yilmaz MI, Saglam M et al.
Lipids in Health and Disease 2015;14:29.
TG/HDL-C ratio: an important prognostic indicator of risk
Comparison of non-HDL-cholesterol versus triglycerides-to-HDL-cholesterol ratio in relation to cardiometabolic risk factors and preclinical organ damage in overweight/obese children: The CARITALY study.
Di Bonito P, Valerio G, Grugni G et al.
Nutr Metab Cardiovasc Dis 2015;25:489-94.
Is HDL-C a predictor of lower extremity amputation in diabetes?
HDL cholesterol as a predictor for the incidence of lower extremity amputation and wound-related death in patients with diabetic foot ulcers.
Ikura K, Hanai K, Shinjyo T, Uchigata Y.
More insights into PCSK9 inhibitor therapy and cardiovascular outcomes
Lowering triglycerides to modify cardiovascular risk: new review
Diabetes and cardiovascular disease in China
Jackson Heart Study: metabolic syndrome, diabetes and subclinical atherosclerosis in African Americans
Relations Between Subclinical Disease Markers and Type 2 Diabetes, Metabolic Syndrome, and Incident Cardiovascular Disease: The Jackson Heart Study.
Xanthakis V, Sung JH, Samdarshi TE et al.
Diabetes Care 2015 Mar 12 [Epub ahead of print]
Presence of diabetic retinopathy may increase risk of future CV events
Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy.
Alonso N, Traveset A, Rubinat E et al.
Cardiovascular Diabetology 2015, 14:33
Much to be done to improve awareness and control of dyslipidaemia in China
Elevated serum remnant-like cholesterol linked to coronary plaque development
Genetic variants of APOA5 predispose to atherogenic dyslipidaemia and subclinical atherosclerosis
Diabetic retinopathy signs related to an increased risk of ESRD
Retinal microvascular abnormalities and risk of renal failure in Asian populations.
Yip WF, Sabanayagam C, Teo BW et al.
PLoS ONE 2015;10(2): e0118076.
Atherogenic index: simple measure for assessing the risk of type 2 diabetes
Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus.
Zhu XW, Deng FY, Lei SF.
Prim Care Diabetes 2015;9:60-7.
Fibroblast growth factor 21: a contributor to residual cardiovascular risk?
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL, Januszewski AS, O'Connell R et al.
EUROASPIRE IV: attainment of lipid targets still falls short
Triglyceride-rich lipoproteins and their remnants; a key driver of dyslipidaemia in type 2 diabetes;
New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
Taskinen MR, Borén J.
PCSK9 associated with atherogenic dyslipidaemia
Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidemia in patients with high cardiovascular risk.
Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L
Clin Sci (Lond) 2015 Feb 4. [Epub ahead of print]
Novel apolipoprotein C-II mimetic peptide: future potential in targeting triglycerides?
A Novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.
Amar MJ, Sakurai T, Sakurai-Ikuta A, Sviridov D, Freeman L, Ahsan L, Remaley AT.
J Pharmacol Exp Ther 2015;352:227-35.
Impact of diabetic retinopathy in working age individuals
US Diabetes and obesity costs updated
Life years lost and lifetime healthcare expenditures associated with diabetes in the U.S., National Health Interview Survey, 1997–2000.
Leung MM, Pollack LM, Colditz GA, Chang SH.
Diabetes Care 2014 [Epub ahead of print]
Does microvascular disease predict macrovascular disease?
Usefulness of retinal microvascular endothelial dysfunction as a predictor of coronary artery disease.
Al-Fiadh AH, Wong TY, Kawasaki R, Clark DJ, Patel SK, Freeman M, Wilson A, Burrell LM, Farouque O.
Am J Cardiol 2014 [Epub ahead of print].
CETP gene-diet interaction impacts atherogenic dyslipidaemia
CETP genotype and changes in lipid levels in response to weight-loss diet intervention: gene-diet interaction analysis in the POUNDS LOST and DIRECT randomized trials.
Qi Q, Durst R, Schwarzfuchs D, Leitersdorf E, Shpitzen S, Li Y, Wu H, Champagne CM, Hu FB, Stampfer MJ, Bray GA, Sacks FM, Shai I, Qi L.
J Lipid Res 2014 [Epub ahead of print].
Triglycerides in the news
Atherogenic dyslipidaemia: how to treat?
Genetic polymorphisms protect from development of atherogenic dyslipidaemia in HIV
Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner.
Echeverría P, Guardiola M, González M et al.
J Int AIDS Soc 2014;17(4 Suppl 3):19557.
HDL cholesterol efflux and cardiovascular disease
Importance of triglycerides as a risk factor in middle-aged women
Decision tree analysis of traditional risk factors of carotid atherosclerosis and a cutpoint-based prevention strategy.
Qin G, Luo L, Lv L et al.
PLoS One 2014;9:e111769.
Metabolic syndrome components linked with decreased glomerular filtration rate
Association of metabolic syndrome with decreased glomerular filtration rate among 75,468 Chinese Adults: A cross-sectional study.
Song H, Wang X, Cai Q et al.
PLoS One 2014;9:e113450.
Nonfasting remnant cholesterol levels as mediator of obesity-related ischaemic heart disease risk
Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease.
Varbo A, Benn M, Davey Smith G et al.
Circ Res 2014 [Epub ahead of print].
Spain: High prevalence of atherogenic dyslipidaemia in lipid clinics
CEPHEUS Study: Lipid control far from optimal in Middle East
Chemokine ligand 2: a potential target in diabetic retinopathy?
Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy.
Rangasamy S, McGuire PG, Franco Nitta C et al.
PLoS ONE 2014;9(10):e108508.
FATS-Observational Study: combination lipid therapy reduces atherosclerotic burden
Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: A case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS).
Phan BA, Moore AB, Davis J et al.
J Clin Lipidol 2014; 8:489-93
Triglycerides: a key predictor of mortality in type 2 diabetes
Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study.
Miselli M-A, Dalla Nora E, Passaro A, Tomasi F, Zuliani G.
Cardiovascular Diabetology 2014, 13:135.
More from PREDI-MED: Mediterranean diet can reverse metabolic syndrome
Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial.
Babio N Toledo E, Estruch R et al; for the PREDIMED Study Investigators.
CMAJ 2014 [Epub ahead of print].
USA National Lipid Association publishes recommendations for management of dyslipidaemia
ODYSSEY COMBO II: PCSK9 inhibitor alirocumab in high cardiovascular risk patients on statin therapy
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study.
Cannon CP, Cariou B, Blom D et al.
ESC Congress, Hotline II. 31 August, 2014 [Abstract 2123].
Antisense inhibitor of apolipoprotein C-III improves the atherogenic lipoprotein profile
Antisense inhibitor of apoC-III produces significant decreases in apoC-III and triglycerides and increases in HDL-C as a single agent or in combination with fibrates in hypertriglyceridemic patients.
Alexander VJ, Gaudet D, Brisson D et al.
Eur Heart J 2014;35(Abstract Supplement):218-219. Abstract P1275.
K-877, a SPPARM, favourably influences postprandial metabolism of remnant lipoproteins
A novel potent and selective PPARalpha agonist, K-877, ameriolates the atherogenic profile of fasting and postprandial hypertriglyceridemia in mice.
Masuda D, Kobayashi T, Nakaoka H et al.
Eur Heart J 2014;35( Abstract Supplement):904. Abstract: P5145.
Atherogenic dyslipidaemia associated with increased coronary artery progression in diabetes
Progression of coronary atherosclerosis: importance of adequate lipid control in diabetic patients.
Hernando Marrupe L, Suarez Cuervo A, Hernandez Antolin R et al.
Eur Heart J 2014;35(Abstract Supplement): 393-394. Abstract P2281.
FOCUS: a polypill strategy improves treatment adherence in post-MI patients
Fasting and postprandial triglycerides: similarly effective as predictors for cardiovascular events
BMI plus visceral adipose tissue improves prediction of cardiovascular risk
Impact of body mass index and visceral adipose tissue on cardiovascular risk factors and outcomes.
Kunimura A, Uetani T, Harada K et al.
Eur Heart J 2014;35(Abstract Supplement):558. [Abstract P3185].
Incretin-based therapies favourably impact metabolic and cardiovascular risk
The effect of incretin-based therapies on metabolic and cardiovascular parameters in diabetic patients: A meta-analysis of 28 randomized control trials with 10171 patients.
Klepacka A, Nikfar S, Rizzo M et al.
Eur Heart J 2014;35(Abstract Supplement): 740. [Abstract: P4239]
More from HPS2-THRIVE and AIM-HIGH: Serious harm with niacin
Safety profile of extended-release niacin in the AIM-HIGH Trial.
Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, Probstfield JL.
N Engl J Med 2014;371:288-90.
Atherogenic dyslipidaemia linked with residual cardiovascular risk in patients with cerebrovascular disease
Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients.
Sirimarco G, Labreuche J, Bruckert E, Goldstein LB, Fox KM, Rothwell PM, Amarenco P; on behalf of the PERFORM and SPARCL Investigators and Committees.
Stroke 2014;45: 1429-36.
PCSK9, triglycerides and cardiovascular risk
Does increased CETP activity underlie the risk of premature atherosclerotic risk in South Asians?
Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians.
Rashid S, Sniderman A, Melone M, Brown PE, Otvos JD, Mente A, Schulze K, McQueen MJ, Anand SS, Yusuf S.
Eur J Prev Cardiol 2014; DOI: 10.1177/2047487314528461.
Elevated triglycerides and CHD risk: the Cohort Norway project
ICARIA study: Detection of atherogenic dyslipidaemia improves CV risk stratification
Prevalence of atherogenic dyslipidemia: Association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study.
Cabrera M, Sánchez-Chaparro MA, Valdivielso P, Quevedo-Aguado L, Catalina-Romero C, Fernández-Labandera C, Ruiz-Moraga M, González-Santos P, Calvo-Bonacho E; ICARIA (Ibermutuamur CArdiovascular RIsk Assessment) Study Group.
**STOP-PRESS: FIRST trial fails primary endpoint**
Da Qing Diabetes Prevention Study: importance of sustained lifestyle intervention
Intestinal insulin signalling, atherogenic dyslipidaemia and metabolic syndrome
Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects.
Veilleux A, Grenier E, Marceau P, Carpentier AC, Richard D, Levy E.
Arterioscler Thromb Vasc Biol 2014;34:644-53.
Will lipidomics offer new possibilities as biomarkers of metabolic syndrome susceptibility?
Plasma lipidome is independently associated with variability in metabolic syndrome in Mexican American families.
Kulkarni H, Meikle PJ, Mamtani M et al.
J Lipid Res 2014; Epub ahead of print.
Periodontal disease: a novel cardiovascular risk factor?
High prevalence of atherogenic dyslipidaemia in Turkey: a public health issue
Overprescription of statins: need to target all risk factors to impact CVD
Comparison of application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European cohort.
Kavousi M, Leening MJG, Nanchen D et al.
JAMA 2014: doi:10.1001/jama.2014.2632.
Peripheral microvascular dysfunction predicts residual vascular risk
Peripheral microvascular dysfunction predicts residual risk in coronary artery disease patients on statin therapy.
Matsue Y, Yoshida K, Nagahori W, Ohno M, Suzuki M, Matsumura A, Hashimoto Y, Yoshida M.
DYSIS-Middle East: High prevalence of atherogenic dyslipidaemia in statin-treated patients
Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment.
Al Sifri SN, Almahmeed W, Azar S, Okkeh O, Bramlage P, Jünger C, Halawa, Ambegaonkar B, Wajih S, Brudi P.
Plos One 2014: DOI: 10.1371/journal.pone.0084350.
High triglyceride/HDL-C ratio predicts CVD in US population
Triglyceride-to-High-Density-Lipoprotein-Cholesterol Ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men.
Vega GL, Barlow CE, Grundy SM, Leonard D, Defina LF.
J Investig Med 2014;62:345-9.
High TG/HDL-C ratio is associated with risk of CKD in the Japanese population
Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: Analysis in a large Japanese population.
Tsuruya K, Yoshida H, Nagata M, Kitazono T, Hirakata H, Iseki K, Moriyama T, Yamagata K, Yoshida H, Fujimoto S, Asahi K, Kurahashi I, Ohashi Y, Watanabe T.
Mendelian randomisation study: Does genetically low triglycerides reduce risk?
Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study.
Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG.
Clin Chem 2014 [Epub ahead of print]
!!!!Stop Press!!!! Updated R3i Macrovascular Position Paper published
Residual macrovascular risk in 2013: what have we learned?
Residual macrovascular risk in 2013: what have we learned?
Fruchart J-C, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr; Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Millán Núñez-Cortés J, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoglu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P, for the Residual Risk Reduction Initiative (R3i)
Cardiovascular Diabetology 2014;
ETC-1002 reduces non-HDL-C in type 2 diabetes patients with hypercholesterolaemia
Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol–lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
Gutierrez MJ, Rosenberg NL, MacDougall DE et al.
Arterioscler Thromb Vasc Biol 2014 [Epub ahead of print].
Atherogenic dyslipidaemia linked with hepatic steatosis
Relation of hepatic steatosis to atherogenic dyslipidemia.
Makadia SS, Blaha M, Keenan T, Ndumele C, Jones S, DeFilippis A, Martin S, Kohli P, Conceicao R, Carvalho J, Nasir K, Blumenthal R, Santos RD
Am J Cardiol 2013;112:1599-604.
Hypertriglyceridaemia: EAS Consensus Panel recommends simple redefinition to aid management
Renal lipid metabolism and diabetic nephropathy
Being sedentary increases cardiometabolic risk
Increasing objectively measured sedentary time increases clustered cardiometabolic risk: a 6 year analysis of the ProActive study.
Wijndaele K, Orrow G, Ekelund U, Sharp SJ, Brage S, Griffin SJ, Simmons RK.
Diabetologia 2013; [Epub ahead of print].
APOE genotype, atherogenic dyslipidaemia and sleep apnoea
Is parental lifespan a factor influencing cardiometabolic risk?
HDL functionality, metabolism do not influence aortic valve stenosis risk
Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans.
Arsenault BJ, Dubé MP, Brodeur MR, de Oliveira Moraes AB, Lavoie V, Kernaleguen AE, Guauque-Olarte S, Mathieu P, Pibarot P, Messika-Zeitoun D, Bossé Y, Rhainds D, Rhéaume E, Tardif JC.
ATVB Published online before print December 12, 2013. doi:10.1161/ATVBAHA.113.302730
Remnant cholesterol: state of the art review
Genetic variants influence hepatic clearance of remnant triglyceride-rich lipoproteins
Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects.
Matikainen N, Burza MA, Romeo S, Hakkarainen A, Adiels M, Folkersen L, Eriksson P, Lundbom N, Ehrenborg E, Orho-Melander M, Taskinen MR, Borén J.
PLoS One 2013;8(11):e79473. doi: 10.1371/journal.pone.0079473.
Managing residual cardiovascular risk: overview of therapeutic options
NAFLD: Emerging mechanisms and potential targets
Retinol binding protein 4 linked with triglycerides in obesity
Fenofibrate and diabetic retinopathy
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes.
Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL.
OSLER trial: mid-term data for PCSK9 monoclonal antibody, evolocumab (AMG 145)
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS; for the OSLER Investigators
Circulation 2013 Nov 19. [Epub ahead of print].
EUROASPIRE III: Atherogenic dyslipidaemia still poorly controlled
Novel therapy: antisense oligonucleotide apolipoprotein C-III inhibitor
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burkey J, Crooke ST, Crooke RM.
Circ Res 2013;112:1479-90.
Potential benefit of dietary n-3 fatty acids on incident AMI in patients with diabetes
Dietary intake of n-3 long-chain polyunsaturated fatty acids and risk of myocardial infarction in coronary artery disease patients with or without diabetes mellitus: a prospective cohort study.
Strand E, Pedersen ER, Svingen GF, Schartum-Hansen H, Rebnord EW, Bjørndal B, Seifert R, Bohov P, Meyer K, Hiltunen JK, Nordrehaug JE, Nilsen DW, Berge RK, Nygård O.
BMC Med 2013;11(1):216.
Insulin resistance down-regulates key intestinal genes involved in lipoprotein metabolism
Where to HDL? Consensus statement from the National Lipid Association
High-density lipoproteins: A consensus statement from the National Lipid Association.
Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, DAgostino RB Sr, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ.
J Clin Lipidol 2013;7:484-525.
Re-thinking non-HDL-C targets in high-risk patients with residual hypertriglyceridemia?
Non-HDL cholesterol, guideline targets, and population percentiles for secondary prevention in a clinical sample of 1.3 million adults The Very Large Database of Lipids (VLDL-2 Study).
Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP, McEvoy JW, Al-Hijji MA, Kulkarni KR, Kwiterovich PO, Blumenthal RS, Jones SR.
J Am Coll Cardiol 2013. [Epub ahead of print 21 Aug].
Inflammation and residual cardiovascular risk
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events following maximally intensive statin therapy.
Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ.
Circulation 2013. [Epub ahead of print Sep 16].
AIM-HIGH: Lipoprotein(a) is a contributor to residual cardiovascular risk
HDL-C: not an appropriate risk marker in secondary prevention
News flash!! New International Atherosclerosis Society Position Paper on Management of Dyslipidaemia
TG/HDL-C ratio: a screening tool to evaluate success in reducing anti-diabetic therapy with weight loss?
Triglyceride/HDL ratio as a screening tool for predicting success at reducing anti-diabetic medications following weight loss.
Palamaner Subash Shantha G, Kumar AA, Kahan S, Irukulla PK, Cheskin LJ.
PLoS One 2013 Jul 15;8(7):e69285.
Does HDL complexity explain the failure of recent trials?
Reconstituted High-Density Lipoprotein (CSL112) improves ABCA1-dependent cholesterol efflux
Increased burden of metabolic syndrome in HIV
Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon
Ngatchou W, Lemogoum D, Ndobo P, Yagnigni E, Tiogou E, Nga E, Kouanfack C, Van de Borne P, Hermans MP
Vasc Health Risk Manag 2013;9:1-9.
Pathogenesis of metabolic syndrome in African Americans
Aldosterone, C-Reactive Protein, and plasma B-Type Natriuretic Peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: Findings From the Jackson Heart Study.
Musani SK, Vasan RS, Bidulescu A, Liu J, Xanthakis V, Sims M, Gawalapu RK, Samdarshi TE, Steffes M, Taylor HA, Fox ER
Diabetes Care 2013 [Epub ahead of print].
New CVD guidelines from Japan Atherosclerosis Society
Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan -2012 Version
Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K.
J Atheroscler Thromb 2013 May 11. [Epub ahead of print].
Low adiponectin increases risk of peripheral artery disease
Sleep apnoea and cardiometabolic risk
State of the art review: The potential of the next generation PPARs
Modelling for causal factors in prediabetes
Dysfunctional HDL implicated in the association of ESRD and CVD
Role of HDL dysfunction in end-stage renal disease: a double-edged sword.
Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K.
J Ren Nutr 2013;23:203-6.
Challenges in managing obesity-related lipid disorders in children – a role for fibrates?
Role of apolipoproteins E and AV in clearance of triglyceride-rich lipoproteins
ADVANCE: Moderate/vigorous activity improves macro- and microvascular outcomes
Atherosclerosis: not just a modern disease
Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations.
Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD, Al-Tohamy Soliman M, Frohlich B, Mininberg DT, Monge JM, Vallodolid CM, Cox SL, Abd el-Maksoud G, Badr I, Miyamoto MI, el-Halim Nur el-din A, Narula J, Finch CE, Thomas GS.
Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations.
FIELD study: total bilirubin predictive of amputation in type 2 diabetes
FIELD study investigators. Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Chan KH, OConnell RL, Sullivan DR, Hoffmann LS, Rajamani K, Whiting M, Donoghoe MW, Vanhala M, Hamer A, Yu B, Stocker R, Ng MK, Keech AC; FIELD study investigators
Potential of PPAR agonists in reducing cardiovascular risk
ALT associated with atherogenic lipoprotein profile
The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study
C. Lorenzo, A. J. Hanley, M. J. Rewers, S. M. Haffner
Novel adipokine linked with obesity and the metabolic syndrome
WISP2 regulates preadipocyte commitment and PPARy activation by BMP4
Hammarstedt A, Hedjazifar S, Jenndahl L, Gogg S, Grünberg J, Gustafson B, Klimcakova E, Stich V, Langin D, Laakso M, Smith U.
Proc Natl Acad Sci U S A 2013;110:2563-8.
Better metabolic health with physical activity
Long-term leisure-time physical activity and serum metabolome
Kujala UM, Mäkinen VP, Heinonen I, Soininen P, Kangas AJ, Leskinen TH, Rahkila P, Würtz P, Kovanen V, Cheng S, Sipilä S, Hirvensalo M, Telama R, Tammelin T, Savolainen MJ, Pouta A, OReilly PF, Mäntyselkä P, Viikari J, Kähönen M, Lehtimäki T, Elliott P, Vanhala MJ, Raitakari OT, Järvelin MR, Kaprio J, Kainulainen H, Ala-Korpela M.
Risk/benefit issues of potent statins
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance J-P, Levy A, Garg AX, Ernst P, Canadian Network for Observational Drug Effect Studies (CNODES).
BMJ 2013;346:f880 doi: 10.1136/bmj.f880
CT-defined non-alcoholic fatty liver associated with atherogenic dyslipidemia
Nonalcoholic fatty liver disease and serum lipoproteins: The Multi-Ethnic Study of Atherosclerosis
Defilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, Budoff MJ.
PRISMA: improvement in metabolic risk in type 2 diabetes
Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in type 2 diabetic patients.
Genovese S, Passaro A, Brunetti P, Comaschi M, Cucinotta D; PRISMA study group, Egan CG, Chinea B, Bravi F, Di Pietro C. Pioglitazone
J Endocrinol Invest 2013 Mar 19. [Epub ahead of print].
New genetic locus for triglycerides in Mexicans
Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci.
Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, Deere KA, Cruz-Bautista I, Arellano-Campos O, Muñoz-Hernandez LL, Gomez-Munguia L, Ordoñez-Sánchez ML, Reddy PM, Lusis AJ, Matikainen N, Taskinen MR, Riba L, Cantor RM, Sinsheimer JS, Tusie-Luna T, Pajukanta P.
J Med Genet 2013 Mar 15. [Epub ahead of print].
Link between atherogenic dyslipidemia and obstructive sleep apnoea syndrome
What is the future role of novel lipid-modifying therapies?
Residual cardiometabolic risk is characterized by elevated visceral adipose tissue and liver fat
Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA.
Smith J, Nazare JA, Borel AL et al.
Diabetes Obes Metab 2013 [Epub January 28, 2013].
An elevated triglyceride/HDL-C ratio is predictive of cardiovascular disease
Identifying cardiovascular disease risk and outcome: use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria
Salazar MR, Carbajal HA, Espeche WG et al
J Intern Med 2013 [Epub January 19, 2013].
Combination fenofibric acid-statin treatment improves management of atherogenic dyslipidemia
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies
Roth EM, Rosenson RS, Jones PH et al.
. J Clin Lipidol 2012;6:534-44.
Elevated cardiovascular risk factors evident up to 30 years before diabetes diagnosis
Early-adulthood cardiovascular disease risk factor profiles among individuals with and without diabetes in the Framingham Heart Study
Rosner Preis S, Pencina MJ, Mann DM et al.
Diabetes Care 2013; [Epub January 22, 2013].
Exercising more and watching less TV reduces the risk of metabolic syndrome in later life.
Television viewing and low leisure-time physical activity in adolescence independently predict the metabolic syndrome in mid-adulthood
Wennberg P, Gustafsson PE, Dunstan DW et al.
Diabetes Care 2013; [Epub January 22, 2013].
Should the focus of guidelines change to reflect increasing cardiometabolic disease?
EUROASPIRE: Continuing high residual cardiovascular risk in Europe
High ratio of HDL-apoCIII/ VLDL-apoCIII predictive of coronary risk
Dietary intervention improves metabolic risk profile
Elevated apolipoprotein E strongly linked to atherogenic dyslipidemia
Dual peroxisome proliferator-activated receptor agonists: therapeutic potential in cardiometabolic disease?
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Rosenson RS, Wright RS, Farkouh M, Plutzky J.
Am Heart J 2012;164:672-80.
Neck circumference is an indicator of atherogenic dyslipidemia
Neck circumference is correlated with triglycerides and inversely related with HDL-cholesterol beyond BMI and waist circumference.
Vallianou NG, Evangelopoulos AA, Bountziouka V et al.
Diabetes Metab Res Rev 2012 Nov 8. doi: 10.1002/dmrr.2369. [Epub ahead of print]
Fibroblast growth factor 21 (FGF21) may be a marker of fenofibrate-mediated reduction in cardiovascular risk
Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
Ong KL, Rye KA, OConnell R et al.
J Clin Endocrinol Metab 2012 Nov 8. [Epub ahead of print].
Aminotransferase levels are associated with cardiometabolic risk
Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: The Framingham Heart Study
Porter SA, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Fox CS.
Arterioscler Thromb Vasc Biol 2012 Nov 15. [Epub ahead of print].
Combination fibrate/statin therapy improves short-term cardiovascular events in ACS
Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data
Tenenbaum A, Medvedofsky D, Fisman EZ et al.
PLoS One 2012;7:e35298.
HDL functionality: relevance to atheroprotection
Novel biological functions of high-density lipoprotein cholesterol.
Mineo C, Shaul PW
Circ Res 2012;111:1079-90.
Genetic predisposition to atherogenic dyslipidaemia linked with type 2 diabetes risk
Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts
Qi Q, Liang L, Doria A, Hu FB, Qi L.
Atherogenic ratio: an index of residual macrovascular risk in women with type 2 diabetes
The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females.
Hermans MP, Ahn SA, Rousseau MF.
Lipids in Health and Disease 2012, 11:132 doi:10.1186/1476-511X-11-132.
Persistent high prevalence of atherogenic dyslipidemia in Indians living in urban areas
FABP4: potential marker of incident atherogenic dyslipidemia
Atherogenic dyslipidaemia implicated in cardiovascular risk in familial hypercholesterolaemia?
The logarithm of the triglyceride/HDL-cholesterol ratio is related to the history of cardiovascular disease in patients with familial hypercholesterolemia.
Soška V, Jarkovský J, Ravcuková B et al.
Clin Biochem 2012;45:96-100.
Higher triglyceride-HDL ratio predisposes to diabetes
Higher ratio of triglyceride to high-density lipoprotein cholesterol may predispose to diabetes mellitus: 15-year prospective study in a general population.
He S, Wang S, Chen X et al.
Elevated triglycerides and low HDL predictive of cardiovascular events in China
Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: A 15-year follow-up of the Chinese Multi-provincial Cohort Study.
Liu J, Wang W, Wang M et al.
Diabetes Res Clin Pract 2012;96:217-24.
Elevated triglycerides predictive of onset and severity of diabetic nephropathy
Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review.
Hellemons ME, Kerschbaum J, Bakker SJ et al.
Diabet Med 2012;29:567-77.
Elevated triglycerides predictive of distal peripheral neuropathy
The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country.
Katulanda P, Ranasinghe P, Jayawardena R et al.
Diabetol Metab Syndr. 2012 May 29;4:21. [Epub ahead of print].
Emerging role for metabolic syndrome components in diabetic neuropathy?
Diabetic neuropathy: clinical manifestations and current treatments.
Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL
Lancet Neurol 2012;11:521-34
Association between the atherogenic index (logarithm of the triglyceride/HDL-cholesterol ratio) and cardiovascular disease in patients with familial hypercholesterolemia
The logarithm of the triglyceride/HDL-cholesterol ratio is related to the history of cardiovascular disease in patients with familial hypercholesterolemia.
Soska V, Jarkovsky J, Ravcukova B, Tichy L, Fajkusova L, Freiberger T
Clin Biochem. 2011 Nov 18
Significant regression of coronary atherosclerosis in patients treated with maximal doses of atorvastatin and rosuvastatin: the SATURN trial
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
Stephen J. Nicholls, M.B., B.S., Ph.D., Christie M. Ballantyne, M.D., Philip J. Barter, M.B., B.S., Ph.D., M. John Chapman, Ph.D., D.Sc., Raimund M. Erbel, M.D., Peter Libby, M.D., Joel S. Raichlen, M.D., Kiyoko Uno, M.D., Marilyn Borgman, R.N., Kathy Wolski, M.P.H., and Steven E. Nissen, M.D.
N Engl J Med 2011; 365:2078-2087
Intensive glucose lowering treatment challenged by a meta-analysis
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al
BMJ 2011; 343:d4169
A review on microvascular residual risk and recent fenofibrate trials
New nomenclature of HDL particles
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events.
Rosenson RS, Brewer HB Jr, Chapman MJ, et al
Clin Chem. 2011 Mar;57(3):392-410
Triglycerides and cardiovascular disease: a scientific statement from the AHA
Lipid biomarkers, but not nonlipid biomarkers predict major cardiovascular events in patients treated with atorvastatin
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers
Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators.
Journal of American College of Cardiology 2011;57(1):63-9
Atherogenic lipid profile in patients with inflammatory bowel disease
Despite statin therapy, a large proportion of patients with diabetes do not reach lipid-lowering goals
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries.
Hermans MP, Castro Cabezas M, Strandberg T, Ferrieres J, Feely J, Elisaf M, Michel G, Sansoy V.
Curr Med Res Opin. 2010 Feb;26(2):445-54.
Refocusing on HDL as a therapeutic target
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels
Grover SA;Kaouache M;Joseph L;Barter P;Davignon J;
Archives of Internal Medicine 2009;169:1775-80.
TG/HDL-C: a key predictor of coronary risk
Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men
Cordero A;Andres E;Ordonez B;Leon M;Laclaustra M;Grima A;Luengo E;Moreno J;Bes M;Pascual I;Civeira F;Pocovi M;Alegria E;Casasnovas JA;MEtabolic Syndrome Active Subjects Study Investigators;
American Journal of Cardiology 2009;104:1393-7.
Cholesterol treatment has improved, but high-risk women are still undertreated
Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2
Santos RD;Waters DD;Tarasenko L;Messig M;Jukema JW;Ferrieres J;Verdejo J;Chiang CW;L-TAP 2 Investigators;
American Heart Journal 2009;158:860-6.
An HDL-related factor predicts vascular events in coronary patients treated with statins
Lower HDL-cholesterol is a strong and independent predictor of both cardiac and all-cause death in patients with left ventricular dysfunction
Epicardial endothelial dysfunction correlates with LDL and HDL particle size
Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy
Ford MA;McConnell JP;Lavi S;Rihal CS;Prasad A;Sandhu GS;Hartman SJ;Lerman LO;Lerman A;
Atherosclerosis 2009 May 6. [Epub ahead of print]
High plasma HDL-C levels protect against risk of stroke
Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project
Asplund K;Karvanen J;Giampaoli S;Jousilahti P;Niemela M;Broda G;Cesana G;Dallongeville J;Ducimetriere P;Evans A;Ferrieres J;Haas B;Jorgensen T;Tamosiunas A;Vanuzzo D;Wiklund PG;Yarnell J;Kuulasmaa K;Kulathinal S;MORGAM Project;
Additive effects of routine blood pressure lowering and intensive glucose control on mortality and albuminuria in patients with type 2 diabetes
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial
Zoungas S;de Galan BE;Ninomiya T;Grobbee D;Hamet P;Heller S;MacMahon S;Marre M;Neal B;Patel A;Woodward M;ADVANCE Collaborative Group;Cass A;Glasziou P;Harrap S;Lisheng L;Mancia G;Pillai A;Poulter N;Perkovic V;Travert F;
Diabetes Care 2009;32:2068-74.
Two-fold increase in risk of chronic kidney disease in Taiwanese subjects with hypertriglyceridemia
High rate of silent coronary artery disease in patients with diabetic retinopathy
Low HDL cholesterol levels are associated with cardiovascular disease in hypertensive Spanish women
High-density lipoprotein cholesterol and cardiovascular disease in Spanish hypertensive women. The RIMHA study
Coca A;Cea-Calvo L;Lozano JV;Inaraja V;Fernandez-Perez C;Navarro J;Bonet A;Redon J;Representación del Grupo de los Investigadores del Estudio RIMHA;
Revista Española de Cardiología 2009;62:1022-31.
Is decreased HDL particle size associated with increased CHD risk?
HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study
Arsenault BJ, Lemieux I, Després JP, Gagnon P, Wareham NJ, Stroes ES, Kastelein JJ, Khaw KT, Boekholdt SM.
Atherosclerosis. 2009 Feb 12.
Incidence of chronic kidney disease reduced by 24% in patients with type 2 diabetes and high HDL cholesterol levels
Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.
Zoppini G, Targher G, Chonchol M, Perrone F, Lippi G, Muggeo M.
Nutr Metab Cardiovasc Dis. 2009 Feb 2.
Significant reduction of non-fatal stroke but nonsignificant decrease in primary end point of cardiovascular events in peripheral artery disease patients on aspirin
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials
Berger JS;Krantz MJ;Kittelson JM;Hiatt WR;
A meta-analysis of 32 studies shows that elevated triglycerides are an independent risk factor for coronary heart disease
Ethnic differences in lipid profile changes associated with physical activity
High prevalence of hypertriglyceridemia but low use of TG-lowering medications in the US
HDL-C =60 mg/dL associated with more than 50% decrease in 8-year mortality after percutaneous coronary intervention in patients LDL-C <70 mg/dL
Preventing cardiovascular risk associated with triglycerides in patients with acute coronary syndromes
ApoB/apoA-1 ratio best predictor of major coronary events in the IDEAL
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)
Holme I;Cater NB;Faergeman O;Kastelein JJ;Olsson AG;Tikkanen MJ;Larsen ML;Lindahl C;Pedersen TR;on behalf of the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering Study Group;
Annals of Medicine 2008;40:456-64.
Statin therapy reduces major cardiovascular events in individuals with normal LDL-C and elevated CRP levels
JUPITER Study Group.Collaborators (1332) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ;
N Engl J Med. 2008 Nov 20;359(21):2195-207
Low-dose aspirin does not reduce the risk of first cardiovascular events in Japanese patients with type 2 diabetes
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators.
JAMA. 2008 Nov 12;300(18):2134-41.
Nonfasting triglycerides predict increased risk of cardiovascular events
Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction.
Langsted A, Freiberg JJ, Nordestgaard BG.
Circulation. 2008 Nov 11;118(20):2047-56
In high-risk patients intolerant to angiotensin-converting enzyme inhibitors: Favourable effects of telmisartan
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators.
Ezetimibe/simvastin + fenofibrate in patients with mixed hyperlipidemia: favourable effects of on atherogenic lipoprotein subclasses
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB.
J Lipid Res. 2008 Jul 31.
Intensive lipid lowering in patients with coronary artery disease, diabetes, and chronic kidney disease associated with marked reduction in cardiovascular events
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators.
Mayo Clin Proc. 2008 Aug;83(8):870-9.
Retinopathy: an independent predictor of coronary heart disease-related mortality
Retinopathy Predicts Coronary Heart Disease Mortality.
Liew G, Wong T, Mitchell P, Cheung N, Wang JJ.
Heart. 2008 Aug 12.
Very low HDL-C levels linked to a worse prognosis in non-ST-segment elevation acute coronary syndromes
Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes.
Roe MT, Ou FS, Alexander KP, Newby LK, Foody JM, Gibler WB, Boden WE, Ohman EM, Smith SC Jr, Peterson ED.
Eur Heart J. 2008 Aug 20
Persistence of abnormal lipid profile in approximately 60% of patients achieving total and LDL-cholesterol targets
Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data
Belsey J, de Lusignan S, Chan T, van Vlymen J, Hague N.
Curr Med Res Opin. 2008 Sep;24(9):2551-60.
In the study, MMP9 serum levels were measured in 157 CCS patients (mean age 58 years, 66% male) undergoing coronary computed tomography angiography at baseline and at follow up. Progression of total, fibrous, fibro-fatty, necrotic core, and dense calcium plaque volumes (PV) were evaluated. Serum MMP9 was associated with significant annual increases in total and necrotic core PV (p= 0.017 and p = 0.038, respectively), which were independent of traditional cardiovascular risk factors, medications, and the presence of obstructive coronary artery disease. The authors concluded that MMP9 was an independent predictive marker of progression of adverse coronary plaques and proposed that measurement of blood MMP9 may have potential for identifying patients with elevated residual risk despite optimal management of classical cardiovascular risk factors.